ArticleJournal of clinical medicine2021
The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A Case Report of Refractory Allergic Bronchopulmonary Aspergillosis: The Art of Selection, Discontinuation and Switching Biologics.Journal of inflammation research · 2026Article
- Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.Journal of asthma and allergy · 2026Article
- From FEVJournal of asthma and allergy · 2026Review
- Efficacy of Omalizumab against Japanese Cedar pollinosis in clinical practice.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- Discontinuation of biologic therapy in severe asthma: Evidence and strategies for safe withdrawal: A scoping review.The World Allergy Organization journal · 2025Review
- Severe Asthma in the Era of Biologics: Continuous Challenges.Journal of clinical medicine · 2023Article
- Review
- Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma.Asthma research and practice · 2022Review
- Therapeutic Modalities for Asthma, COPD, and Pathogenesis of COVID-19: Insights from the Special Issue.Journal of clinical medicine · 2022Article
- Predictors of a Minimal Clinically Important Difference Following Omalizumab Treatment in Adult Patients With Severe Allergic Asthma.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The implications of boosting Omalizumab treatment (OT) in patients with severe allergic asthma (SAA) remain unclear. The study aimed to explore and compare the 12-month effectiveness between continuous, at least 10-month OT (continuation group) and four-month boost of Omalizumab (boost group) in adult patients with SAA. In this retrospective cohort study, clinical data were collected for further analysis. Of all participants (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.